Alnylam Q3 revenue rises 149% to $1.25 billion and raises 2025 product revenue guidance
Alnylam reported third-quarter 2025 total revenues of $1.25 billion, up from $501 million a year earlier, and GAAP net income of $251 million, or $1.84 per diluted share, compared with a net loss of $112 million a year earlier. The company raised its full-year 2025 total net product revenue guidance to $2.95 billion to $3.05 billion, but also disclosed a subpoena from the U.S. Attorney's Office for the District of Massachusetts about government price reporting.
Key points
- Q3 2025 total revenues were $1.25 billion versus $501 million in Q3 2024, including $300 million of Roche milestone revenue recognized in September 2025.
- GAAP net income was $251 million, or $1.84 per diluted share, versus a GAAP net loss of $112 million, or $0.87 per share, a year earlier.
- Full-year 2025 total net product revenue guidance was raised to $2.95 billion to $3.05 billion, from $2.65 billion to $2.8 billion.
- The company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts seeking documents on government price reporting for AMVUTTRA, ONPATTRO, OXLUMO and GIVLAARI.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.